LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults (LATE-COVID)
14. mars 2021 oppdatert av: Maciej Banach, Polish Mother Memorial Hospital Research Institute
Complications Post COVID-19 - Observational Study in Children and Adults
All consecutive patients admitted to the Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland between 1st October 2020 and 31st December 2021 due to symptoms, which might reflect complications following COVID-19, will be included in the observational cohort study.
Data concerning clinical characteristics, results of laboratory tests, other studies, such as: echocardiography, 24 hours ambulatory ECG recording will be collected.
The study is planned also to be extended with the genetic predisposition in children to COVID-19 late complications (within independent grant).
Studieoversikt
Status
Ukjent
Forhold
Detaljert beskrivelse
A wide range of complications have been linked to COVID-19 - the coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
It is well known that COVID-19 affects multiple organs.
Most of the data however present the early complications during the acute phase of the infection, and there is still a lack of knowledge on the late complications that might appear after recovery.
Additionally, the long-term complications in patients who were asymptomatic or had mild symptoms during the acute phase of infection, not requiring hospitalization, oxygen therapy or mechanical ventilation has not been fully studied.
Therefore, our aim was to assess factors related to the severity of post-COVID complications among patients without severe symptoms in the acute phase of COVID-19.
The study will include consecutive COVID-19 convalescents (the infection of coronavirus was confirmed with real-time polymerase chain reaction test or positive result of autoantibodies) admitted to the Departments of Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland, for complications.
Both children and adults will be included in the study.
The patients will have laboratory testing and other studies due to the character of symptoms.
Studietype
Observasjonsmessig
Registrering (Forventet)
500
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Lodz, Polen, 93-338
- Rekruttering
- Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland
-
Ta kontakt med:
- Maciej Banach, MD,PhD,FNLA,FAHA,FESC,FASA
- Telefonnummer: +48 42 2711124
- E-post: maciej.banach@icloud.com
-
Ta kontakt med:
- Joanna Lewek, MD, PhD
- Telefonnummer: +48 422721593
- E-post: joanna.lewek@umed.lodz.pl
-
Hovedetterforsker:
- Maciej Banach, MD,PhD,FNLA,FAHA,FESC,FASA
-
Underetterforsker:
- Joanna Lewek, MD, PhD
-
Underetterforsker:
- Izabela Jatczak-Pawlik, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
All consecutive COVID-19 convalescents admitted to the Departments of Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland, for complications
Beskrivelse
Inclusion Criteria:
- consecutive COVID-19 convalescents (the infection of coronavirus was confirmed with real-time polymerase chain reaction test or positive result of autoantibodies) admitted to the Departments of Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland, for complications
Exclusion Criteria:
- no history of COVID-19 infection,
- lack of complications post COVID-19,
- severe course of Sars-COV-2 infection,
- lack pf patient's agreement to be included in the study
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Adult patients with complications post COVID-19
|
|
Children with complications post COVID-19
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with severe post-COVID-19 complications
Tidsramme: Baseline
|
Data concerning clinical characteristics, results of laboratory tests, other studies, such as: echocardiography, 24 hours ambulatory ECG recording will be collected.
According to the results patients will be qualified to severe or mild complication group
|
Baseline
|
|
Factors related to the severity of post-COVID-19 complications
Tidsramme: Baseline
|
Data concerning clinical characteristics, results of laboratory tests, other studies, such as: echocardiography, 24 hours ambulatory ECG recording will be collected to verify which of them can be related to the severity of post-COVID-19 complications.
|
Baseline
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Post-COVID SCORE
Tidsramme: Baseline
|
We aim to create a post-COVID SCORE that helps to predict the risk of late complications both in children and adults.
|
Baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020 Jul 10;11:1648. doi: 10.3389/fimmu.2020.01648. eCollection 2020.
- Parsamanesh N, Karami-Zarandi M, Banach M, Penson PE, Sahebkar A. Effects of statins on myocarditis: A review of underlying molecular mechanisms. Prog Cardiovasc Dis. 2021 Jul-Aug;67:53-64. doi: 10.1016/j.pcad.2021.02.008. Epub 2021 Feb 20.
- Petrovic V, Radenkovic D, Radenkovic G, Djordjevic V, Banach M. Pathophysiology of Cardiovascular Complications in COVID-19. Front Physiol. 2020 Oct 9;11:575600. doi: 10.3389/fphys.2020.575600. eCollection 2020.
- Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in Relation to COVID-19: Should We Care about It? J Clin Med. 2020 Jun 18;9(6):1909. doi: 10.3390/jcm9061909.
- Lewek J, Jatczak-Pawlik I, Maciejewski M, Jankowski P, Banach M. COVID-19 and cardiovascular complications - preliminary results of the LATE-COVID study. Arch Med Sci. 2021 Mar 18;17(3):818-822. doi: 10.5114/aoms/134211. eCollection 2021.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. oktober 2020
Primær fullføring (Forventet)
30. juni 2022
Studiet fullført (Forventet)
30. juni 2022
Datoer for studieregistrering
Først innsendt
14. mars 2021
Først innsendt som oppfylte QC-kriteriene
14. mars 2021
Først lagt ut (Faktiske)
16. mars 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. mars 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. mars 2021
Sist bekreftet
1. mars 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- LATE-COVID
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .